Numorphan (oxymorphone) / Endo - LARVOL DELTA

[Long-term opioid therapy in chronic noncancer pain : A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26weeks.] (PubMed) - "LtOT can be considered in carefully selected and monitored CNCP patients who experience clinically meaningful pain reduction with at least tolerable AE in short-term opioid therapy."

Journal • Biosimilar • Immunology • Inflammation • Oncology • Osteoarthritis • Pain

Levorphanol as a Second Line Opioid in Cancer Patients (clinicaltrials.gov) - P1; N=86; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Jan 2020 ➔ Jan 2021; Trial primary completion date: Jan 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Oncology

Levorphanol as A Second Line Opioid in Reducing Pain in Participants With Cancer (clinicaltrials.gov) - P1; N=86; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Jan 2019 ➔ Jan 2020; Trial primary completion date: Jan 2019 ➔ Jan 2020

Clinical • Trial completion date • Trial primary completion date